LINC01343 and breast cancer: On the other hand, LINC01343 also showed significant overexpression at stage III of BC (|−dct| = 4 and p=0.0032), as well as nonmenopause ages (|−dct| = 4 and p=0.0024) compared to the control group (Figure 7(d) and 7(e)).